CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Dihydropyrimidine Dehydrogenase Testing for Fluoropyrimidine Toxicity

Last updated: February 5, 2021
Project Number: RB1549-000
Product Line: Rapid Response
Research Type: Other Diagnostics
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What are the evidence-based guidelines regarding the use of dihydropyrimidine dehydrogenase testing before treatment with fluoropyrimidine (i.e., 5-fluorouracil and capecitabine) in patients being treated for cancer?

Key Message

One evidence-based guideline was identified regarding the use of dihydropyrimidine dehydrogenase testing before treatment with fluoropyrimidine (i.e., 5-fluorouracil and capecitabine) in patients being treated for cancer.